MLN2238 - Ixazomib

Based on 20 reference(s) in Google Scholar 80 100 20

Axon 2556

CAS [1072833-77-2]

MF C14H19BCl2N2O4
MW 361.03

  • Purity: 98%
  • Soluble in DMSO



Selective and reversible inhibitor of the β5 subunit sites of the 20S proteasome with antitumor activity in various malignancies. MLN2238 exhibits improved pharmacodynamics and antitumor activity compared with bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models. 

MLN2238 is also available as the more stable citrate prodrug MLN9708 (Axon 2557).

KEYWORDS: MLN2238 | supplier | Proteasome inhibitor | Ixazomib | MLN-2238 | CAS [1072833-77-2] | Ubiquitin | Proteasome 20S | Inhibitor | β5 subunit | B-cell lymphoma | FDA approved | MLN 9708

Size Unit Price Stock
5 mg €85.00 In Stock
25 mg €295.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €140.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...